Ulcerative Colitis (Moderate to Severe) | Decision Base | US | 2015
What Are Physician and Payer Expectations as New Mechanisms of Action Transform the Market Landscape?
Significant opportunity remains for therapies to treat moderate to severe ulcerative colitis (UC), particularly for drugs with novel mechanisms of action that more effectively elicit mucosal healing, maintain and sustain long-term disease remission, and improve patients’ quality of life relative to the leading TNF-? inhibitor, infliximab. Current therapies for moderate to severe UC are associated with insufficient efficacy, sometimes serious safety concerns, and a high burden of delivery. Given that the cell adhesion molecule (CAM) inhibitor vedolizumab (Takeda’s Entyvio) recently launched and the oral Janus-activated kinase (Jak) inhibitor tofacitinib (Pfizer’s Xeljanz) is in late-stage development for UC, the competition in the TNF-refractory space is intensifying as companies try to differentiate their novel therapies and capture market share.
